Search Results for: About
Greek study will use the highest dosage of Vitamin K2 as MK-7 so far, further proof of MenaQ7® K2 safety. Oslo, Norway and East Brunswick, NJ (8 June 2021) – Ex-NattoPharma is excited to announce that a new 1.5-year clinical trial using MenaQ7® Vitamin K2 as MK-7 has been registered on ClinicalTrials.gov. The trial … Continue reading MenaQ7 K2 Cardio Study Registered
Greek study will use the highest dosage of Vitamin K2 as MK-7 so far, further proof of MenaQ7® K2 safety.
Oslo, Norway and East Brunswick, NJ (8 June 2021) – Ex-NattoPharma is excited to announce that a new 1.5-year clinical trial using MenaQ7® Vitamin K2 as MK-7 has been registered on ClinicalTrials.gov. The trial will examine the cardiovascular impact in a patient population and will use the highest dosage of K2 as MK-7 to date: 1mg daily.
The new multi-centre, placebo-controlled, randomized, open-label intervention clinical trial, “The Effect of Vitamin K2 Supplementation on Arterial Stiffness and Cardiovascular Events in PEritonial DIAlysis (VIKIPEDIA)”, will be conducted with Peritoneal Dialysis (PD) patients. The investigators at Aristotle University of Thessaloniki in Greece will study the effect of K2 supplementation (through normalization of dp-ucMGP) on arterial stiffness and the occurrence of cardiovascular events.
Chronic Kidney Disease (CKD) is a state of progressive vascular calcification and cardiovascular disease. End Stage Kidney Disease patients receive renal replacement therapy either by hemodialysis or by PD, according to lead researcher Stefanos Roumeliotis , MD, PhD. “Several studies have shown that hemodialysis patients have vitamin K depletion and accelerated vascular calcification ,and this finding led to the initiation of several randomized controlled trials exploring the effect of vitamin K2 supplementation on vascular calcification in hemodialysis patients.
“VIKIPEDIA is the first study to assess whether high dosage of Menaquinone-7 could improve arterial stiffness, mortality, cardiovascular disease, 24-hour ambulatory blood pressure and dialysis efficacy in patients with PD,” he explains. “MenaQ7® was chosen to be used in the study because the compound showed its efficacy to improve vitamin K status in many clinical trials with kidney patients.”
At baseline, all eligible patients who have provided a written, informed consent will be enrolled in the study. Αortic stiffness and vitamin K status will be assessed by PWV and plasma dp-ucMGP levels respectively. Before randomization, the investigators will draw blood (serum and plasma) and PD fluid samples from all patients to measure blood count and routine biochemical parameters, including urea, creatinine, potassium, sodium, calcium, phosphorus, c-reactive protein, alkaline phosphatase, albumin, parathormone, 25-OH D3, magnesium, glycated hemoglobin, thyroid function hormones. Since both vitamin D and magnesium are considered of utmost importance in vitamin K metabolism, after baseline, patients with vitamin D and/or magnesium depletion will be treated with oral supplements to achieve normal levels of both elements, before randomization. The cohort will then be categorized to one of the two groups (placebo or active group) and the treatment period will last 1.5 years. To ensure that the two parallel groups will include patients that will not differ significantly in vitamin K and stiffness, patients will be accordingly stratified. After randomization, all patients will continue their routine, standard medical treatment and patients in the treatment group will additionally receive daily, per 1 mg of vitamin K2 (MenaQ7®, ex-Nattopharma, ASA, Hovik, Norway).
It is important to note, according to Dr. Hogne Vik, Chief Medical Officer with ex-NattoPharma, that researchers recognized the importance of optimal level of vitamin D and magnesium to support function of vitamin K2. That is why patients deficient with vitamin D or magnesium will be treated with theses nutrients to reach normal levels before randomization.
“People with kidney problems exhibits low vitamin K status, which has been shown to increase cardiovascular disease as well as mortality risk,” explains Dr. Vik. “Vitamin K2 supplementation was shown to be effective to improve vitamin K status in kidney patients to some extent. However, none of these trials have been conducted in PD patients, but only in pre-dialysis CKD or haemodialysis subjects or kidney transplant patients.
“VIKIPEDIA represents two important firsts: it will be the first trial in PD patients, and the first time this high dosage of vitamin K2 as MK-7 will be used, which supports high safety profile of this nutrient,” adds Dr. Vik. “We are thrilled because this study will add to the already substantial evidence that MenaQ7 Vitamin K2 is an important cardiovascular-support nutrient, and it presents great hope for an at-risk patient population.”
The study is scheduled to start in September 2021. The researchers will collaborate with long-time ex-NattoPharma research partner Masstricht University to evaluate vitamin K status.
https://clinicaltrials.gov/ct2/show/NCT04900610?term=peritoneal&cond=vitamin+k&draw=2&rank=1
About ex-NattoPharma
As the Vitamin K2 world leader, ex-NattoPharma’s ironclad science portfolio is the foundation for today’s understanding of K2 and is the basis for all industry claims about the benefits of K2.
Two things separate ex-NattoPharma from other Vitamin K2 suppliers. First, we offer the ONLY K2 as MK-7 clinically validated to deliver health benefits. With more than 20 human clinical trials where MenaQ7 K2 was the actual source material, we have demonstrated the K2 mechanism, safe and effective dosages, and the importance of K2 for bone and cardiovascular health, all while simultaneously verifying our brand’s efficacy.
Second, NattoPharma provides the MOST comprehensive K2 portfolio – both natural fermented and nature-identical synthesis in various dilutions and solubilities – offering solutions for brand owners to make Vitamin K2 available in a broader range of finished product dose forms. The MenaQ7® Solution Platform opens opportunities to formulate with multiple active ingredients, guided by the experts of the ex-NattoPharma R&D team.
A ex-NattoPharma partnership does not end once kilos are delivered. We are invested in your success and positioned to ensure you achieve it.
Our Videos
More Videos About Vitamin K2!
MenaQ7 is featured in quality products around the globe.
Make your Milk Powder as Proactive to Health as Your Consumers Are!
Consumers show a greater interest in functional products and ingredient claims than ever before, as they seek out products that offer a convenient health boost.
62% of consumers in Asia-Pacific identify “Overall Health” as the critical concern resulting from COVID-19.
Fortification is an opportunity for differentiation
Learn more about the most important vitamin consumers may never have heard of!
Adding vitamin K2 to milk powder ensures calcium is guided to building bone and diverted away from soft tissue
MenaQ7®️ K2 is clinically proven to support the needs of healthy bones in children.
Kids – Growing Strong Bones
Clinical research show children taking 45 mcg of MenaQ7® resulted in improved vitamin K status and stronger, denser bones. Milk powder as a delvery format represent an opportunity to mitigate deficency and to support children growing strong bones.
Supporting Bone Health in
Postmenopausal Women
Maintaining the best possible cardiovascular and bone health are two of the most critical areas allowing women to age in a healthy way.
MenaQ7® is the only Vitamin K2 clinically proven to protect bone strength and density in postmenopausal women.
MenaQ7® K2 is clinically proven to support bone and heart health in adults.
MenaQ7® K2 is clinically proven to support bone and heart health in adults.
Vitamin K2 is Key for Healthy Ageing
Being fearful for poor bone and cardiovascular health can be a hindrance for the growing population of senior citizens to engage in activities, travel, and exercise
Calcification is believed to be an unfortunate result of aging, but studies show that arterial calcification is, in fact, an actively regulated process.
MenaQ7® Vitamin K2 taken daily is not only shown to inhibit age-related arterial stiffening but improve vascular elasticity.
Knapen MHJ et al. Thrombosis and Haemostasis, 2015; 19;113(5).
The Only Clinically Proven K2 now available in milk powders!
Providing solutions to make Vitamin K2 available in a broader range of finished product dose forms is at the heart of the NattoPharma R&D team.
Vitamin K2 creates synergies for health and is the better together vitamin to supercharge other vital nutrients like vitamin D, Calcium and Omega3 to strengthen solid foundational health across all stages in life.
Adding MenaQ7® K2 to milk powders will ensure calcium is optimally trapped to the bone matrix and away from arteries where it can do harm.
Learn how K2 has Better Together Synergies with vitamin D for bone and cardiovascular health www.menaq7.com/bettertogether
You Have The Questions,
We Have The Answers
Is MenaQ7 compatible in milk powder?
MenaQ7® Vitamin K2 is now offered in a solution developed specifically for milk powder compatibility
- Stability protocol available
- No flavour or odour to interfere with the finished product
Are consumers interested in K2?
NattoPharma has educated the health supplement industry and has all the tools you need to tell the K2 story to consumers, we will show you how!
How do I know vitamin K2 will be bioavailable from dairy?
Study show drinkable yogurt fortified with MenaQ7 Vitamin K2 provided the same bioavailability as supplements.
What about safety and efficacy?
MenaQ7 is proven safe and efficacious in 20+ clinical trials.
Book a K2 Meeting in Your Calendar Today
Copyright Ⓒ 2015 MenaQ7. All Rights Reserved. MenaQ7 Vitamin K2 is a trademark of MattoPharma ASA.
New grant will fund substantiating MenaQ7 Vitamin K2 effect on calcium metabolism The Norwegian Research Council has awarded a grant to ex-NattoPharma to fund a 4-year project to document the effects of calcium metabolism in the body based on the presence or absence of Vitamin K2, MK7. The project will utilize ex-NattoPharma’s MenaQ7® Vitamin K2 … Continue reading Norwegian Research Council Grant
New grant will fund substantiating MenaQ7 Vitamin K2 effect on calcium metabolism
The Norwegian Research Council has awarded a grant to ex-NattoPharma to fund a 4-year project to document the effects of calcium metabolism in the body based on the presence or absence of Vitamin K2, MK7. The project will utilize ex-NattoPharma’s MenaQ7® Vitamin K2 as MK-7 and the research part will be conducted at the Maastricht University in the Netherlands in the Department of Biochemistry under the guidance of Dr. Leon Schurgers, Senior Scientist and Associate Professor of Biochemistry at Maastricht and CARIM, the Cardiovascular Research Institute of Maastricht.
In this research, Nattopharma together with the Maastricht University will study the utilisation of calcium in preclinical models for postmenopausal bone loss and chronic kidney failure to determine how supplemental calcium is metabolized in the presence or absence of supplemental vitamin K2, MK7.
“This study will help to provide further evidence that calcium without adequate Vitamin K2 consumption might end up in the soft tissues where it is not wanted, rather than in the bone matrix, where it is needed,” says Dr. Schurgers. In a recent study by “Bolland et al. it was shown that calcium supplementation of postmenopausal women was associated a beneficial effect on bone, but also with increased myocardial infarction, suggesting detrimental effects on the vascular system possibly by increased vascular calcification. As calcium supplementation is needed for bone, the precipitation in the vessel wall needs to be inhibited.”
Vitamin K2’s role as a cardiovascular supporter
Ex-NattoPharma is rightfully excited about this new study, which should add to the evidence confirming Vitamin K2’s role as a cardiovascular supporter, including the ground-breaking three-year interventional study[1] the company sponsored that confirmed adding 180mcg of MenaQ7® Vitamin K2 as MK-7 to one’s daily intake improves arterial health and flexibility.
“This will be the first study that demonstrates K2’s impact on calcium metabolism in vivo; however, we have shown in human studies with healthy participants that the progression of hardening of the arteries can be halted and even regressed,” adds Dr. Hogne Vik, ex-NattoPharma Chief Medical Officer. “Calcium supplement manufacturers must recognize the importance of pairing calcium with Vitamin K2. They cannot ignore the growing body of evidence that K2 is required for the body to properly metabolize and utilize calcium.”
Reference:
1 Knapen MH et al, Braam LAJL, Drummen NE, Bekers O, Hoeks APG, Vermeer C. Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women: double-blind randomised clinical trial. Thrombosis and Haemostasis. 2015 113 5: 1135-1144. doi: 10.1160/TH14-08-0675.
Ex-NattoPharma-sponsored survey revealed consumers are actively pursuing healthier arteries through supplementation. Heart Health ranks as one of the top 3 reasons respondents use dietary supplements. At the request of ex-NattoPharma USA, Inc., Discover Research Group surveyed a total of 380 health- and nutrition-minded individuals regarding heart health in October 2015. The survey focused on answering … Continue reading Consumer Survey Shows Interest in Supplements for Artery Health
Ex-NattoPharma-sponsored survey revealed consumers are actively pursuing healthier arteries through supplementation.
Heart Health ranks as one of the top 3 reasons respondents use dietary supplements.
At the request of ex-NattoPharma USA, Inc., Discover Research Group surveyed a total of 380 health- and nutrition-minded individuals regarding heart health in October 2015. The survey focused on answering three primary questions:
1. How concerned are people with the health of their heart?
2. Do they believe that hard arteries are a problem that is associated with poor heart health?
3. How willing would they be to take a supplement to improve the health of their heart by preventing (and even reversing) the hardening of their arteries?
Key Findings: Of the 380 individuals surveyed:
• 87% currently take vitamins or supplements to improve their health.
• 25% identify themselves as having a condition associated with heart disease; 40% have someone in their immediate family with a condition associated with heart disease.
• 35% are very concerned that hardening of the arteries will have a negative impact on their heart health.
• 67% of those surveyed (n = 380) would take a supplement shown to stop hardening of the arteries if the supplement carried no side effects and is priced about the same as other heart health supplements.
Bone and Heart Health are the top reasons customers supplement (reason 2 and 3, respectively). When asked how concerned they were about their heart health on a scale of 1-7, 62% rated their level of concern as 5 or greater (38% rated their level of concern 6 or greater).
Of those who indicated that they or their family member currently has a heart condition (n=232),
• 84% are currently taking a prescription medicine (55% would consider taking a prescription)
• 44% are currently taking a supplement (59% would consider taking a supplement)
Of those who indicated that they currently do not have a heart condition (n=148), for those surveyed between 30 and 40 years old, supplements would be their No. 1 action if they developed heart disease.
“Just over one-third of survey participants ranked ‘hardening of the arteries’ as one of the top 3 risk factors associated with heart disease. This is a concern with growing awareness with Americans, but a natural solution to address this concern was not previously available,” said Eric Anderson, senior vice president of global sales and marketing with ex-NattoPharma, exclusive global supplier of MenaQ7® Vitamin K2 as MK-7. “However, our clinical trials have shown that MenaQ7 addresses 2 of the top 3 reasons that health-minded consumers supplement: MenaQ7 not only protects against age-related hardening of the arteries and regressed arterial stiffening, but it also has been shown to improve bone mineral density and strength.”
MenaQ7® Vitamin K2 selected by Biolab Farmacêutica, one of Brazil’s largest pharmaceutical cos. Ex-NattoPharma welcomed the opportunity to support the launch of a new product featuring MenaQ7® Vitamin K2 as MK-7, Doiska MenaQ7, for an audience of more than 600 cardiologists in São Paulo, Brazil. “Dois” is “Two” in Portugese, and “ka” signifies “K”. Biolab … Continue reading Product Launch in Brazil
MenaQ7® Vitamin K2 selected by Biolab Farmacêutica, one of Brazil’s largest pharmaceutical cos.
Ex-NattoPharma welcomed the opportunity to support the launch of a new product featuring MenaQ7® Vitamin K2 as MK-7, Doiska MenaQ7, for an audience of more than 600 cardiologists in São Paulo, Brazil. “Dois” is “Two” in Portugese, and “ka” signifies “K”.
Biolab Farmacêutica is one of the largest pharmaceutical companies in Brazil, and the No. 1 pharmaceutical company for cardiology prescriptions. More than 600 cardiologists attended the event hosted by Biolab, and NattoPharma, world leaders in Vitamin K2 research and development, had representatives on hand to explain the substantial body of science supporting MenaQ7 Vitamin K2 as MK-7, specifically the cardiovascular benefits.
“It was our pleasure to participate in the Brazilian launch of Doiska MenaQ7, and a privilege to present our clinical substantiation to more than 600 engaged cardiologists in São Paulo,” says Dr. Hogne Vik, ex-NattoPharma Chief Medical Officer, who presented alongside respected cardiologist Prof. Dr. Francisco Fonseca.
According to Flavio Zemella, Biolab Marketing Director, the symposium was very successful and physicians are excited about Doiska MenaQ7® arrival in the pharmacies, expected by beginning of August this year. “We are confident the partnership between ex-NattoPharma and Biolab will be very fruitful as we foresee the product will benefit thousands of Brazilians across the country.”